Acceleron Pharma Inc. Sustainability Profile
Acceleron Pharma Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for rare diseases and serious health conditions. Founded in 2004, Acceleron has made significant strides in the industry, particularly in the fields of pulmonary and muscle-related disorders. The company is renowned for its unique approach to harnessing the power of the Transforming Growth Factor-beta (TGF-β) superfamily, which underpins its core products, including the groundbreaking treatment for pulmonary arterial hypertension. With a strong commitment to research and development, Acceleron has positioned itself as a key player in the biopharmaceutical landscape, achieving notable milestones that underscore its dedication to improving patient outcomes.
DitchCarbon Score
How does Acceleron Pharma Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acceleron Pharma Inc.'s score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acceleron Pharma Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Merck & Co., Inc., and thus may inherit climate commitments and targets from its parent organisation. As part of its corporate family relationship, Acceleron Pharma Inc. aligns with the sustainability initiatives and targets set by Merck & Co., Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the second cascade level. However, specific reduction targets or achievements for Acceleron Pharma Inc. have not been disclosed. In the context of industry standards, the lack of reported emissions data suggests that Acceleron Pharma Inc. is in the early stages of formalising its climate commitments. The company may benefit from the established frameworks and initiatives of its parent company, which are designed to enhance sustainability and reduce carbon footprints across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 626.29 | 000,000,000,000,000 | 000,000,000,000,000 |
| Scope 2 | 245.3 | 000,000,000,000,000 | 000,000,000,000,000 |
| Scope 3 | - | 0,000,000,000,000,000 | 0,000,000,000,000,000 |
How Carbon Intensive is Acceleron Pharma Inc.'s Industry?
How Carbon Intensive is Acceleron Pharma Inc.'s Location?
Acceleron Pharma Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acceleron Pharma Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.